Videos

James McCloskey, MD, analyzes result data from the QUAZAR AML-001 trial that focused on oral azacitidine.

Cole McCoy, PharmD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP explain the additional agents being studied as maintenance therapy options.

Joe Duarte, co-founder and president of ContinuumMD, discusses a program model that allows pharmacies to provide virtual and in-person primary care options for rural communities with health care access challenges.

Christopher Fine, MD, FACC, a cardiologist at National Jewish Health, discusses how pharmacists can support patients with cancer who have a much higher risk of heart disease.

Lifestyle modifications are the cornerstone of treatment.

A lot of recent studies have focused on how to teach students and residents the Pharmacists' Patient Care Process (PPCP) and how pharmacists are already engaging with the PPCP.

These clear-cut guidelines help pharmacists making sure the patients are getting the right drug to set them up for success and prevent problems down the road.

Pharmacists are already doing a lot of things with the Pharmacists' Patient Care Process, but they haven't always used that language.

The future trend in managing diabetes will extend into glycemic control, weight reduction, and renal liver, for example.

The Pharmacist Patient Care Process provides really consistent language for pharmacists and pharmacy team members to talk about what teams are already doing.

David Pope, PharmD, CDE, the EVP of Innovation and Industry Relations at OmniSYS, discusses the FDA’s announcement updating pharmacists’ prescriptive authority for the COVID-19 antiviral Paxlovid.

By using technology solutions, pharmacists can be further integrated into the care team.

Christine Walko, PharmD, BCOP, FCCP, discusses some new developments for PARP inhibitors in cancer care for patients with homologous recombination deficiency.

Christopher Fine, MD, FACC, a cardiologist at National Jewish Health, discusses the relationship between heart disease and cancer and the importance of the field of cardio-oncology when treating patients with cancer.

In February of this year, the new statistics came out where we're at now 37 million with diabetes and 96 million with prediabetes.

Patient Centered Care is what should be at the heart of a pharmacist's work.

Drs Moore and Dent discuss the impact of oral selective estrogen receptor degraders and modulators in the treatment for HR-positive, HER2-negative breast cancer.

The panel of experts explore the contribution provided by pharmacists in the treatment landscape of patients with HR-positive, HER2-negative breast cancer.

Although treating mental health symptoms is essential, finding the time and energy for more appointments can be challenging for patients with cancer.

Dr James McCloskey discusses patient selection for AML maintenance therapy, as well as novel agents that are being evaluated in this setting.

Thrombocytopenia was the most common adverse effect, which was managed through dose reduction.

The panel describes the various roles and responsibilities for each member of an AML management care team.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss research conducted looking to assess the hematology-oncology pharmacist “great migration” from the field.

Ken Thorpe, PhD, professor of public health at Emory University and chairman of Partnership to Fight Chronic Disease, discusses legislation that the US House of Representatives recently passed to put greater restrictions on the FDA’s accelerated approval pathway.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss the underlying causes of the hematology-oncology pharmacist great migration from the field.

Drs Haumschild, Jain, and Wang discuss clinical pearls regarding BTK inhibitors, including drug interactions.

Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses methods of accomplishing greater workforce diversity in the field of oncology pharmacy.

This panel of experts navigates the effects of BTK inhibitors, and their impact on trpatients with Mantle Cell Lymphoma.

Pharmacy Times spoke with Paul Feuerstadt, MD, FACG, AGAF, about the investigative C. difficile treatment RBX2660.

Bhavesh Shah, RPh, BCOP, steering committee co-chair of the 2022 ATOPP Summit, discusses the impact of the annual ATOPP summit on the oncology pharmacy field.